logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Amit Sehrawat

department of medical oncology hematology
H指数:9
被引数:257

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA®) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India

曲妥珠单抗emtansine生物类似物(UJVIRA®)在早期和转移性HER2阳性乳腺癌中的真实世界疗效与安全性：一项来自印度的多中心合并回顾性分析

Breast Cancer Research and Treatment
IF3
2026-10-280
PRE
Ayesha Mahajan; Soumya Surath Panda; Lalatendu Moharana; M.V. Chandrakanth; Vivek Agarwala; Rupam Manna; S.V. Saju; Susan Honey Raju; Prasanth Ganesan; Gomathi Shankar; Ashwin Oommen Phillip; Sunu Lazar Cyriac; Anil Jose; P. Unnikrishnan; Kanu Priya Bhatia; Amit Sehrawat; Deepak Sundriyal; Himani Dhanai; Lipsita Samantaray; Swati Sucharita Mohanty; Biswajit Dubashi
Neoadjuvant Docetaxel, Cisplatin, and Capecitabine in Borderline-Inoperable Locally Advanced Oral Cavity Squamous Cell Carcinoma: A Prospective Observational Study

新辅助多西他赛、顺铂和卡培他滨治疗边缘不可切除的局部晚期口腔鳞状细胞癌：一项前瞻性观察研究

European Journal of Surgical Oncology
IF2.9
2026-05-050
PRE
Abhimanyu Singh; Manu Malhotra; Amit Sehrawat; Madhu Priya; Abhishek Bhardwaj; null Joyson Antony; Ramesh Prasath; Devendra Singh Chawra; null Vetrivel; Jyoti Choudhary
Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India

PARP抑制剂在BRCA突变或HRD阳性晚期卵巢癌一线维持治疗中的真实世界数据：一项来自印度的多中心回顾性研究

Journal of Ovarian Research
IF4.2
2026-02-070
OAAI
Susheel Kumar Yeshala; Soumya Surath Panda; Lalatendu Moharana; SV Saju; Krishnakumar Rathinam; Susan Honey Raju; Amit Sehrawat; Deepak Sundriyal; Ashwin Oommen Phillip; Pamela Alice Kinsely; Kanu Priya Bhatia; Smita Kayal; Biswajit Dubashi; Sunu Lazar Cyriac; Sathya Natarajan; Lipsita Samantaray; Swati Sucharita Mohanty; Sudam Sadangi; Snehasis Pradhan; Arti Rana; Prasanth Ganesan
Epidemiology, Treatment Patterns, and Survival Outcomes in Patients With Uterine Cancer in a Real-World Setting in India

印度真实世界环境中子宫癌患者的流行病学、治疗模式及生存结局

Indian Journal of Surgical Oncology
IF0.7
2026-01-010
PRE
Bose, Shalini; Khoiwal, Kavita; Rajaram, Shalini; Gaurav, Amrita; Mundhra, Rajlaxmi; Bahadur, Anupama; Chowdhury, Nilotpal; Singh, Ashok; Gupta, Sweety; Joseph, Deepa; Sehrawat, Amit; Sundriyal, Deepak; Kamdi, Parish; Chaturvedi, Jaya
Upfront surgery versus induction chemotherapy followed by surgery in oral cavity squamous cell cancers with advanced nodal disease (SurVIC Trial): a phase 3 multicentre randomised controlled trial

upfront surgery与诱导化疗后手术在伴有进展期淋巴结疾病的口腔癌鳞状细胞癌中的比较（SurVIC试验）：一项多中心随机对照临床试验

BMJ OPEN
IF2.3
2025-10-060
OA
Poonia, Dharma Ram; Sehrawat, Amit; Vishnoi, Jeewan Ram; Sharma, Nivedita; Kumar, Parmod; Devnani, Bharti; Warriere, Aparna; Solanki, Akanksha; Pareek, Puneet; Aggarwal, Divya; Yadav, Taruna; Sharma, Prem Prakash; Gadwal, Ashita; Goyal, Anushka; Elhence, Poonam; Khera, Pushpinder; Jakhetiya, Ashish; Swaim, Pnahindra; Muduly, Dillip; Mahajan, Rohit; Garg, Pankaj; Kumar, Vijay; Kar, Madhabananda; Misra, Sanjeev
The efficacy and safety of mirtazapine vs olanzapine in preventing chemotherapy induced nausea and vomiting in combination with the triplet regimen in patients receiving highly emetogenic chemotherapy: An open label, prospective, randomized control study

米氮平与奥氮平在预防高度催吐性化疗患者中化疗诱导的恶心和呕吐方面的疗效与安全性比较（联合三联方案）：一项开放标签、前瞻性、随机对照研究

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Swamy, A. Mruthyunjaya; Sehrawat, A.; Sundriyal, D.
Clinicopathological profile and outcomes of neuroendocrine tumors: Data from a multicenter collaborative registry in India

神经内分泌肿瘤的临床病理特征与预后：来自印度多中心协作登记研究的资料

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Panda, S. S.; Meedimale, S.; Moharana, L.; Kayal, S.; Dubashi, B.; Rathnam, K. K.; Saju, S. V.; Sehrawat, A.; Sundriyal, D.; Singh, A.; Cyriac, S. L.; Philips, A. O.; Kinslely, P.; Priya, K. B.; Halanaik, D.; Raja, K.; Bh, S.; Natarajan, S.; Ganesan, P.
Real-world data of PARP inhibitors in first-line maintenance for BRCA mutated or HRD positive advanced ovarian cancer: A multicenter retrospective study from India

PARP抑制剂在BRCA突变或HRD阳性晚期卵巢癌一线维持治疗中的真实世界数据：一项来自印度的多中心回顾性研究

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Kumar, Y. S.; Panda, S. S.; Moharana, L.; Samantaray, L.; Saju, S. V.; Rathnam, K. K.; Raju, H. S.; Sehrawat, A.; Sundriyal, D.; Kingsley, P. A.; Priya, K. B.; Kayal, S.; Dubashi, B.; Philips, A. O.; Cyriac, S. L.; Natarajan, S.; Mohanty, S. S.; Ganesan, P.

研究方向

暂未获取到该数据
D
Deepak Sundriyal
H 指数:11论文数:128被引数:418
S
Soumya Surath Panda
H 指数:7论文数:98被引数:410
D
D. Sundriyal
H 指数:1论文数:13被引数:2
M
Mayank Kapoor
H 指数:6论文数:67被引数:134
K
K.K. Rathnam
H 指数:1论文数:13被引数:2
S
Smita Kayal
H 指数:14论文数:170被引数:741
H
H.S. Raju
H 指数:1论文数:10被引数:1
A
Anusha Mruthyunjaya Swamy
H 指数:3论文数:11被引数:77
S
S. V. Saju
H 指数:4论文数:27被引数:103
L
L. Moharana
H 指数:2论文数:13被引数:4